{"ok":true,"trend":{"id":8762,"platform":"news","region":"global","key":"european commission grants marketing authorization for nezglyal® (leriglitazone), the first pharmacological treatment approved for cerebral adrenoleukodystrophy (cald), a rare neurodegenerative diseas","title":"European Commission grants marketing authorization for NEZGLYAL® (leriglitazone), the first pharmacological treatment approved for cerebral adrenoleukodystrophy (cALD), a rare neurodegenerative disease","url":"https://news.google.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?oc=5","first_seen":"2026-09-26T18:15:27.186379Z","last_seen":"2026-09-26T20:53:41.111257Z","last_rank":10,"peak_rank":9,"last_volume":null,"peak_volume":0,"seen_count":3,"score":49.15,"category_hint":"eu_politics","section":"world","category":"eu_politics","summary":"The European Commission has granted marketing authorization for NEZGLYAL (leriglitazone), making it the first pharmacological treatment approved for cerebral adrenoleukodystrophy, a rare and often fatal neurodegenerative disease affecting the brain. The decision offers a new option for patients who previously had no approved drug therapy, and it is being noted as a significant milestone in treatment of rare pediatric neurodegenerative conditions.","why":"The approval marks the first ever authorized drug treatment for a rare disease that previously had none.","tone":"positive","entities":["European Commission","NEZGLYAL","leriglitazone"],"summarized_at":"2026-09-26T20:12:33.098918Z","meta":{"via":"scan","lang":"en","term":"european union","source":"News-Medical","published":"Sat, 26 Sep 2026 04:16:00 GMT"},"nw":0.74,"promo":0.02,"kind":"news_event","importance":1.64,"hidden":false,"hide_reason":null,"judged_at":"2026-09-26T18:15:28.563111Z","title_en":"EU approves first drug for cerebral adrenoleukodystrophy","section_name":"World","category_name":"EU Politics","timeline":[{"captured_at":"2026-09-26T18:15:27.186379Z","rank":9,"volume":null},{"captured_at":"2026-09-26T19:32:50.705565Z","rank":9,"volume":null},{"captured_at":"2026-09-26T20:53:41.111257Z","rank":10,"volume":null}],"posts":[{"platform":"news","url":"https://news.google.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?oc=5","author":"news-medical.net","title":"European Commission grants marketing authorization for NEZGLYAL® (leriglitazone), the first pharmacological treatment approved for cerebral adrenoleukodystrophy (cALD), a rare neurodegenerative disease","snippet":null,"posted_at":"2026-09-26T04:16:00Z","likes":null}],"elsewhere":[],"window":"7d"}}